MedTrace Logo

Safety and Immunogenicity of a Candidate CHIKV Vaccine (CHIK001)

NCT03590392 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2019-10-18

No results posted yet for this study

Summary

A phase I dose escalation study to assess the safety and immunogenicity of the candidate vaccine ChAdOx1 Chik in healthy volunteers.

Volunteers will be recruited and vaccinated in Oxford, England.

All vaccinations will be administered intramuscularly. Three different doses will be tested (5x10\^9 vp, 2.5x10\^10 vp and 5x10\^10vp).

The total duration of the study will be 26 weeks from the day of enrolment for all volunteers.

Conditions

  • Chikungunya Fever

Interventions

BIOLOGICAL

ChAdOx1 Chik

ChAdOx1 Chik, a replication-deficient simian adenoviral vector expressing CHIKV antigens.

Sponsors & Collaborators

  • University of Oxford

    lead OTHER

Principal Investigators

  • Adrian V Hill, DPhill FRCP · Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, United Kingdom

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-31
Primary Completion
2019-09-30
Completion
2019-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03590392 on ClinicalTrials.gov